Publications of Lars Pelz
All genres
Journal Article (6)
2024
Journal Article
108 (1), 240 (2024)
Production of recombinant vesicular stomatitis virus-based vectors by tangential flow depth filtration. Applied Microbiology and Biotechnology
Journal Article
108, pp. 1 - 15 (2024)
Production of antiviral “OP7 chimera” defective interfering particles free of infectious virus. Applied Microbiology and Biotechnology 2023
Journal Article
13, 20936 (2023)
Generation of “OP7 chimera” defective interfering influenza A particle preparations free of infectious virus that show antiviral efficacy in mice. Scientific Reports
Journal Article
15 (9), 1872 (2023)
Broad-Spectrum Antiviral Activity of Influenza A Defective Interfering Particles against Respiratory Syncytial, Yellow Fever, and Zika Virus Replication In Vitro. Viruses 2021
Journal Article
95 (24), e01174-21 (2021)
Semi-continuous propagation of influenza A virus and its defective interfering particles: analyzing the dynamic competition to select candidates for antiviral therapy. Journal of Virology
Journal Article
17, e1009357 (2021)
Multiscale model of defective interfering particle replication for influenza A virus infection in animal cell culture. PLoS Computational Biology Book Chapter (2)
2023
Book Chapter
Upstream processing for viral vaccines - Process intensification. In: Bioprocessing of Viral Vaccines, 1st edition Ed., pp. 137 - 174 (Eds. Kamen, A.; Cervera, L.). CRC Press, Boca Raton (2023)
Book Chapter
Upstream processing for viral vaccines – General aspects. In: Bioprocessing of Viral Vaccines, 1st edition Ed., pp. 79 - 136 (Eds. Kamen , A.; Cervera , L.). CRC Press, Boca Raton (2023)
Meeting Abstract (1)
2022
Meeting Abstract
Scale-Down of an Ortbital Shaken Bioreactor: High Cell Density Cultivation in Perfusion Mode and Virus production. In Proceedings Single-Use Technologies V: Building the Future, 40. Single-Use Technologies V: Building the Future, Marseille, France, March 20, 2022 - March 23, 2022. (2022)
Talk (14)
2023
Talk
Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 17th Vaccine Congress, Glasgow (Scotland) (2023)
Talk
Reverse genetics for Influenza a virus to generate genetically engineered defective interfering particles for antiviral treatment and vaccination. Vir-AI-DIP Workshop , Hamburg (Germany) (2023)
Talk
Intensifiying OSB processes for high titer virus production. 5th large scale meeting: Orbital shaken bioreactors, Girona (Spain) (2023)
Talk
Influenza A virus defective interfering particles as antiviral agents. 32nd Annual Meeting of the Society for Virology (GfV), Ulm (Germany) (2023)
Talk
Influenza A virus OP7 defective interfering particles: Cell culture-based production and antiviral efficacy in vivo. Cell Culture Engineering (CCE) XVIII , Cancun (Mexico) (2023)
Talk
In-depth characterization and cell culture-based production of influenza A virus defective interfering particles. ACTIP fellowship session, Dublin (Ireland) (2023)
Talk
Semi-continuous Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing the Dynamic Competition To Select Candidates for Antiviral Therapy. Vir-AI-DIP Workshop, Hamburg (Germany) (2023)
Talk
Multiscale model of influenza A virus and defective interfering particle co-infection in animal cell culture. Vir-AI-DIP Workshop, Hamburg (Germany) (2023)
2022
Talk
Scale-Down of an Ortbital Shaken Bioreactor: High Cell Density Cultivation in Perfusion Mode and Virus production. Single-Use Technologies V: Building the Future, Marseille, France (2022)
Talk
Long-Term Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing Dynamic Competition to Select Antiviral Candidates. Vaccine Technology VIII, Sitges (Spain) (2022)
Talk
Semi-Continuous propagation of Influenza A virus and its defective interfering particles: Analyzing the dynamic competition to select antiviral candidates. 27th ESACT Meeting, Lisbon (Portugal) (2022)